Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center
Articles by Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center

TRK Fusion Inhibitors in Clinical Practice
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

Key Considerations for Biomarker Testing
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.

Importance of Biomarker Testing for Solid Tumors
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.